

CHAD THERAPEUTICS INC

Form 10-Q

February 10, 2005

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

**Quarterly Report Under Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**For Quarterly Period Ended: December 31, 2004**

Or

**Transition Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Commission file number: 1-12214

**CHAD THERAPEUTICS, INC.**

---

(Exact name of registrant as specified in its charter)

California  
(State of other jurisdiction of  
incorporation or organization)

95-3792700  
(I.R.S. Employer  
Identification No.)

21622 Plummer Street, Chatsworth, CA 91311

---

(Address of principal executive offices) (Zip Code)

(818) 882-0883

---

(Registrant's telephone number, including area code)

---

(Former Address)

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act.)

Yes  No

As of December 31, 2004, the registrant had 10,126,000 shares of its common stock outstanding.



**TABLE OF CONTENTS**

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures about Market Risks

Item 4. Controls and Procedures

Part II

Item 1. Legal Proceedings

Item 2. Changes in Securities, Use of Proceeds and Issuer Purchase of Equity Securities

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Item 6. Exhibits

SIGNATURE

INDEX TO EXHIBITS

Exhibit 31.1

Exhibit 31.2

Exhibit 32

---

**Table of Contents**

CHAD THERAPEUTICS, INC.  
Condensed Balance Sheets  
December 31, 2004 and March 31, 2004  
(Unaudited)

|   | December 31,<br>2004 | March 31,<br>2004 |
|---|----------------------|-------------------|
| <b>ASSETS</b>   |                      |                   |
| Current Assets:   |                      |                   |
| Cash  | \$ 2,021,000         | \$ 2,708,000      |
| Accounts receivable, less allowance for doubtful accounts of \$68,000 at December 31, 2004 and \$68,000 at March 31, 2004 | 3,628,000            | 2,911,000         |
| Inventories, net (Note 2)   | 7,357,000            | 4,989,000         |
| Prepaid expenses  | 349,000              | 233,000           |
| Deferred income taxes   | 691,000              | 224,000           |
| <br>Total current assets  | <br>14,046,000       | <br>11,065,000    |
| <br>Property and equipment, at cost   | <br>5,985,000        | <br>5,789,000     |
| Less accumulated depreciation   | 4,845,000            | 4,571,000         |
| <br>Net property and equipment  | <br>1,140,000        | <br>1,218,000     |
| <br>Intangible assets, net  | <br>700,000          | <br>729,000       |
| Other assets, net   | 87,000               | 31,000            |
| <br>Total assets  | <br>\$ 15,973,000    | <br>\$ 13,043,000 |
| <b>LIABILITIES AND SHAREHOLDERS EQUITY</b>  |                      |                   |
| Current liabilities:  |                      |                   |
| Accounts payable  | \$ 1,839,000         | \$ 502,000        |
| Accrued expenses  | 1,290,000            | 1,185,000         |
| Income taxes payable  | 418,000              | 203,000           |
| <br>Total current liabilities   | <br>3,547,000        | <br>1,890,000     |
| <br>Shareholders' equity:   |                      |                   |
| Common shares, \$.01 par value, authorized 40,000,000 shares; 10,126,000 and 10,096,000 shares issued and outstanding     | 13,360,000           | 13,309,000        |
| Accumulated deficit   | (934,000)            | (2,156,000)       |
| <br>Total shareholders' equity  | <br>12,426,000       | <br>11,153,000    |
| <br>Total liabilities and shareholders' equity  | <br>\$ 15,973,000    | <br>\$ 13,043,000 |

See accompanying notes to condensed financial statements.

---

**Table of Contents**

CHAD THERAPEUTICS, INC.  
Condensed Statements of Operations  
For the three months ended December 31, 2004 and 2003  
(Unaudited)

|                                     | Three Months Ended<br>December 31, |                |
|-------------------------------------|------------------------------------|----------------|
|                                     | 2004                               | 2003           |
| Net sales                           | \$ 6,444,000                       | \$ 5,237,000   |
| Cost of sales                       | 3,741,000                          | 3,017,000      |
| <br>Gross profit                    | <br>2,703,000                      | <br>2,220,000  |
| Costs and expenses:                 |                                    |                |
| Selling, general and administrative | 1,858,000                          | 1,460,000      |
| Research and development            | 380,000                            | 343,000        |
| <br>Total costs and expenses        | <br>2,238,000                      | <br>1,803,000  |
| <br>Operating income                | <br>465,000                        | <br>417,000    |
| Other income                        | 14,000                             | 20,000         |
| <br>Earnings before income taxes    | <br>479,000                        | <br>437,000    |
| Income tax expense (benefit)        | (26,000)                           | 19,000         |
| <br>Net earnings                    | <br>\$ 505,000                     | <br>\$ 418,000 |
| <br>Basic earnings per share        | <br>\$ 0.05                        | <br>\$ 0.04    |
| <br>Diluted earnings per share      | <br>\$ 0.05                        | <br>\$ 0.04    |
| <br>Weighted shares outstanding:    |                                    |                |
| Basic                               | 10,124,000                         | 10,088,000     |
| Diluted                             | 10,647,000                         | 10,401,000     |

See accompanying notes to condensed financial statements.



**Table of Contents**

CHAD THERAPEUTICS, INC.  
Condensed Statements of Operations  
For the six months ended December 31, 2004 and 2003  
(Unaudited)

|                                     | Nine Months Ended<br>December 31, |                |
|-------------------------------------|-----------------------------------|----------------|
|                                     | 2004                              | 2003           |
| Net sales                           | \$ 18,852,000                     | \$ 16,190,000  |
| Cost of sales                       | 11,116,000                        | 9,608,000      |
| <br>Gross profit                    | <br>7,736,000                     | <br>6,582,000  |
| Costs and expenses:                 |                                   |                |
| Selling, general and administrative | 5,306,000                         | 4,771,000      |
| Research and development            | 1,207,000                         | 1,011,000      |
| <br>Total costs and expenses        | <br>6,513,000                     | <br>5,782,000  |
| <br>Operating income                | <br>1,223,000                     | <br>800,000    |
| Other income interest income, net   | 28,000                            | 29,000         |
| <br>Earnings before income taxes    | <br>1,251,000                     | <br>829,000    |
| Income tax expense                  | 29,000                            | 37,000         |
| <br>Net earnings                    | <br>\$ 1,222,000                  | <br>\$ 792,000 |
| <br>Basic earnings per share        | <br>\$ 0.12                       | <br>\$ 0.08    |
| <br>Diluted earnings per share      | <br>\$ 0.12                       | <br>\$ 0.08    |
| <br>Weighted shares outstanding:    |                                   |                |
| Basic                               | 10,119,000                        | 10,080,000     |
| Diluted                             | 10,622,000                        | 10,331,000     |

See accompanying notes to the condensed financial statements.



**Table of Contents**

CHAD THERAPEUTICS, INC.  
 Condensed Statement of Shareholders' Equity  
 For the nine months ended December 31, 2004  
 (Unaudited)

|                              | Common Shares |               | Accumulated    |
|------------------------------|---------------|---------------|----------------|
|                              | Shares        | Amount        | Deficit        |
| Balance as of March 31, 2004 | 10,096,000    | \$ 13,309,000 | \$ (2,156,000) |
| Exercise of stock options    | 30,000        | 51,000        |                |
| Net earnings                 |               |               | 1,222,000      |
| Balance at December 31, 2004 | 10,126,000    | \$ 13,360,000 | \$ (934,000)   |

See accompanying notes to consolidated financial statements.

---

**Table of Contents**

CHAD THERAPEUTICS, INC.  
Condensed Statements of Cash Flows  
For the nine months ended December 31, 2004 and 2003  
(Unaudited)

|   | Nine Months Ended<br>December 31, |              |
|---|-----------------------------------|--------------|
|   | 2004                              | 2003         |
| Cash flows from operating activities:   |                                   |              |
| Net earnings  | \$ 1,222,000                      | \$ 792,000   |
| Adjustments to reconcile net earnings to net cash provided by (used in) operating activities: |                                   |              |
| Depreciation and amortization of property and equipment                                       | 274,000                           | 349,000      |
| Amortization of intangibles   | 29,000                            | 1,000        |
| Changes in assets and liabilities:  |                                   |              |
| Decrease (increase) in accounts receivable  | (717,000)                         | (487,000)    |
| Decrease (increase) in inventories  | (2,368,000)                       | (202,000)    |
| Decrease (increase) in prepaid expenses   | (116,000)                         | 224,000      |
| Decrease (increase) in other assets   | (56,000)                          | (12,000)     |
| Decrease (increase) in deferred income tax  | (467,000)                         |              |
| Increase (decrease) in accounts payable   | 1,337,000                         | (388,000)    |
| Increase (decrease) in accrued expenses   | 105,000                           | (257,000)    |
| Increase (decrease) in income taxes payable   | 215,000                           | 34,000       |
| Net cash provided by (used in) operating activities   | (542,000)                         | 54,000       |
| Cash flows from investing activities:   |                                   |              |
| Additions to other assets   |                                   | (63,000)     |
| Capital expenditures  | (196,000)                         | (235,000)    |
| Net cash used in investing activities   | (196,000)                         | (298,000)    |
| Cash flows from financing activities:   |                                   |              |
| Exercise of stock options   | 51,000                            | 22,000       |
| Net cash provided by financing activities   | 51,000                            | 22,000       |
| Net decrease in cash  | (687,000)                         | (222,000)    |
| Cash beginning of period  | 2,708,000                         | 1,596,000    |
| Cash end of period  | \$ 2,021,000                      | \$ 1,374,000 |

See accompanying notes to condensed financial statements.

---

**Table of Contents**1. **Interim Reporting**

CHAD Therapeutics, Inc. (the Company) is in the business of developing, producing, and marketing respiratory care devices designed to improve the efficiency of oxygen delivery systems for home health care and hospital treatment of patients suffering from pulmonary diseases.

In the opinion of management, all adjustments necessary, which are of a normal and recurring nature, for a fair presentation of the results for the interim periods presented have been made. The results for the three and nine month periods ended December 31, 2004, are not necessarily indicative of the results expected for the year ended March 31, 2005. The interim statements are condensed and do not include some of the information necessary for a more complete understanding of the financial data. Accordingly, your attention is directed to the footnote disclosures found in the March 31, 2004, Annual Report and particularly to Note 1 which includes a summary of significant accounting policies.

2. **Reclassifications**

Certain reclassifications have been made to the prior year's balances to conform to the presentation for the three and nine months ended December 31, 2004.

3. **Inventories**

Inventories in 2004 are summarized as follows:

|                 | December 31  | March 31     |
|-----------------|--------------|--------------|
| Finished goods  | \$ 2,217,000 | \$ 1,223,000 |
| Work-in-process | 1,684,000    | 1,062,000    |
| Raw materials   | 3,456,000    | 2,704,000    |
|                 | \$ 7,357,000 | \$ 4,989,000 |

---

**Table of Contents**4. Earnings Per Common Share

Following is a reconciliation of the numerators and denominators used in the calculation of basic and diluted earnings per common share:

|   | Three Months Ended December<br>31, |            | Nine Months Ended December<br>31, |            |
|---|------------------------------------|------------|-----------------------------------|------------|
|   | 2004                               | 2003       | 2004                              | 2003       |
| Basic earnings per share:                                 |                                    |            |                                   |            |
| Numerator-net earnings                                    | \$ 505,000                         | \$ 418,000 | \$ 1,222,000                      | \$ 792,000 |
| Denominator-weighted average common shares<br>outstanding | 10,124,000                         | 10,088,000 | 10,119,000                        | 10,080,000 |
| Basic earnings per share                                  | \$ 0.05                            | \$ 0.04    | \$ 0.12                           | \$ 0.08    |
| Diluted earnings per share:                               |                                    |            |                                   |            |
| Numerator-net earnings                                    | \$ 505,000                         | \$ 418,000 | \$ 1,222,000                      | \$ 792,000 |
| Denominator:  |                                    |            |                                   |            |
| Weighted average common shares outstanding                | 10,124,000                         | 10,088,000 | 10,119,000                        | 10,080,000 |
| Diluted effect of common stock options                    | 523,000                            | 313,000    | 503,000                           | 251,000    |
|   | 10,647,000                         | 10,401,000 | 10,622,000                        | 10,331,000 |
| Diluted earnings per share                                | \$ 0.05                            | \$ 0.04    | \$ 0.12                           | \$ 0.08    |

Options to purchase 225,000 shares of common stock at prices ranging from \$5.00 to \$12.54 per share and 395,000 shares of common stock at prices ranging from \$2.39 to \$13.47 were not included in the computation of diluted earnings per share for the three and nine month periods ended December 31, 2004 and 2003, respectively, because their effect would have been anti-dilutive.

5. Income Tax Expense

At December 31, 2004, the Company's net deferred tax assets are partially offset by a valuation allowance. The Company will continue to assess the valuation allowance and to the extent it is determined that such allowance is no longer required, the tax benefit of the remaining net deferred tax assets will be recognized in the future. The Company has California net operating loss carryforwards of \$1,535,000, against which a full valuation allowance has been recorded. California suspended the utilization of net operating loss carryforwards during tax years starting in 2002 and 2003. As a result, the Company has been unable to use its California net operating loss carryforwards until the tax year that began April 1, 2004. The California net operating losses expire in 2006.

**Table of Contents****6. Geographic Information**

The Company has one reportable operating segment. Geographic information regarding the Company's sales is as follows:

|                     | Three Months Ended |              | Nine Months Ended |               |
|---------------------|--------------------|--------------|-------------------|---------------|
|                     | December 31,       |              | December 31,      |               |
|                     | 2004               | 2003         | 2004              | 2003          |
| United States       | \$ 6,115,000       | \$ 4,977,000 | \$ 17,768,000     | \$ 15,471,000 |
| Canada              | 82,000             | 67,000       | 238,000           | 213,000       |
| Germany             | 4,000              | 7,000        | 9,000             | 52,000        |
| Japan               | 127,000            | 123,000      | 330,000           | 178,000       |
| All other countries | 116,000            | 63,000       | 507,000           | 276,000       |
|                     | \$ 6,444,000       | \$ 5,237,000 | \$ 18,852,000     | \$ 16,190,000 |

All long-lived assets are located in the United States.

Sales of OXYMATIC® and CYPRESS OXYPneumatic® conservers accounted for 67% and 78% of the Company's sales for the three month periods ended December 31, 2004 and 2003, and 74% and 67% for the nine month periods ended December 31, 2004 and 2003, respectively.

**7. Major Customers**

Four major national chains accounted for 54% and 49% of the Company's net sales for the nine month periods ended December 31, 2004 and 2003, respectively. One chain accounted for 34% and 26% of sales for the nine month periods ended December 31, 2004 and 2003, respectively, and one other chain accounted for 13% and 15% of sales for the nine month periods ended December 31, 2004 and 2003, respectively.

**8. Stock Option Plan**

The company accounts for its stock option plan in accordance with the provisions of Accounting Principles Board Opinion No. 25, *Accounting for Stock Issued to Employees*, and related interpretations. The Company has also adopted the pro forma disclosure provisions of Statement of Financial Accounting Standards (SFAS) No. 123, *Accounting for Stock-Based Compensation*, which permits entities to provide pro forma net income and pro forma net earnings per share disclosures as if the fair-value-based method defined in SFAS 123 had been applied.

The Company applies Accounting Principles Board Opinion No. 25 in accounting for the Plan and no compensation expense has been recognized for its stock options in the accompanying financial statements. The following table illustrates the effect on net earnings and earnings per share if the Company had applied the fair value recognition provision of FASB Statement No. 123, *Accounting for Stock Based Compensation*, to stock-based employee compensation:

**Table of Contents**

|   | Three Months Ended |            | Nine Months Ended |            |
|---|--------------------|------------|-------------------|------------|
|   | December 31,       |            | December 31,      |            |
|   | 2004               | 2003       | 2004              | 2003       |
| Net earnings, as reported   | \$ 505,000         | \$ 418,000 | \$ 1,222,000      | \$ 792,000 |
| Deduct: Total stock based employee compensation expense<br>determined under fair value-based method for all awards,<br>net of related tax effects | 27,000             | 18,000     | 82,000            | 77,000     |
| Pro forma net income  | \$ 478,000         | \$ 400,000 | \$ 1,140,000      | \$ 715,000 |
| Earnings per share:   |                    |            |                   |            |
| Basic as reported   | \$ 0.05            | \$ 0.04    | \$ 0.12           | \$ 0.08    |
| Basic pro forma   | 0.05               | 0.04       | 0.11              | 0.07       |
| Diluted as reported   | 0.05               | 0.04       | 0.12              | 0.08       |
| Diluted proforma  | 0.04               | 0.04       | 0.11              | 0.07       |

---

**Table of Contents**

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

CHAD Therapeutics, Inc. (the Company) develops, assembles and markets medical devices that furnish supplementary oxygen to home health care patients. The Company was a pioneer in developing oxygen conserving devices that enhance the quality of life for patients by increasing their mobility and, at the same time, lower operating costs by achieving significant savings in the amount of oxygen actually required to properly oxygenate patients. The market for oxygen conserving devices has been and continues to be significantly affected by increased competition, consolidation among home oxygen dealers and revisions (and proposed revisions) in governmental reimbursement policies. All of these factors, as described more fully below, have contributed to a more competitive market for the Company's products, as devices that were less expensive but which provided lower oxygen savings (or, in some cases, did not truly provide ambulatory oxygen) have achieved some level of success.

The current procedures for reimbursement by Medicare for home oxygen services provide a prospective flat fee monthly payment based solely on the patient's prescribed oxygen requirement. Under this system, inexpensive concentrators have grown in popularity because of low cost and less frequent servicing requirements. At the same time, oxygen conserving devices, such as the Company's products, have also grown in popularity due to their ability to extend the life of oxygen supplies and reduce service calls by dealers, thereby providing improved mobility for the patient and cost savings for dealers.

In addition, other changes in the health care delivery system, including the increase in the acceptance and utilization of managed care, have stimulated a significant consolidation among home oxygen dealers. Major national and regional home medical equipment chains have continued to expand their distribution networks through the acquisition of independent dealers in strategic areas. Margins on sales to national chains are generally lower due to quantity pricing and management anticipates continued downward pressure on its average selling price. Four major national chains accounted for approximately 54% and 49% of the Company's net sales, for the nine month periods ended December 31, 2004 and 2003, respectively. One chain accounted for 34% and 26% of sales for the nine month periods ended December 31, 2004 and 2003, respectively, and one other chain accounted for 13% and 15% of sales for the nine month periods ended December 31, 2004 and 2003, respectively. This increased dependence on a limited number of large customers may result in greater volatility and unpredictability of future operating results as changes in the purchasing decisions by one or more major customers can have a material affect upon our financial statements.

The Company believes that price competition, continuing industry consolidation and competitive products with features not found in the Company's products prior to the introduction of the OM-400 and CYPRESS OXYPneumatic® series conservers discussed below adversely affected sales during the three years ending March 31, 2001. To combat the erosion in sales of the oxygen conserver product line, the Company developed and introduced several new products in this area. The first of these, the OXYMATIC® 401

---

**Table of Contents**

conservor, received 501(k) clearance from the Food and Drug Administration in June 2000, and shipments of the new product began in July 2000. The second, the OXYMATIC 411 conservor, was cleared in December 2000 and shipments began in January 2001. The third, the OXYMATIC 401A and 411A conservors, received clearance in March 2001 with shipments beginning that month. The SEQUOIA OXYMATIC 300 series conservors began shipping in December 2001, and the Company began shipment of the CYPRESS OXYPneumatic conservor in July 2002. The Company received clearance from the FDA to market its newest oxygen conserving device, the LOTUS Electronic Oxygen Conservor, in October 2004 with plans to begin shipment of the new device in February 2005. The LOTUS Electronic Oxygen Conservor weighs less than a pound and will be offered with or without a breath-sensing alarm. It will also offer additional liter flow settings and an extended battery life of up to four months of normal usage on two AA-size batteries. Management believes the features and improvements in these products have enabled the Company to regain some of the market share lost in the conservor market prior to 2001 and reestablish the Company as a leader in the conservor market.

In May of 2004, the Company received clearance from the FDA to market its new SAGE Oxygen Therapeutic Device. The SAGE device is the first in a planned family of oxygen therapeutic devices that use the Company's proprietary technologies to sense a patient's movements and automatically adjust the rate of oxygen delivery to reduce the risk of desaturation as activity increases. This device combines the industry's first truly dynamic delivery technology with the proven oxygen sensor technology in the OXYMATIC 400 series conservors. As a result, the new SAGE Oxygen Therapeutic Device addresses the common problem of oxygen desaturation, which causes a patient to feel weak and out of breath when activity increases, while it still improves patient ambulatory capability. This new device underscores the Company's dedication to providing home care suppliers and their patients with the widest range of home oxygen choices to suit individual needs, preferences and disease conditions. The Company began selling the SAGE nationwide in October 2004. No estimate can currently be made regarding the level of success the Company may achieve with this line of products or when the additional therapeutic devices that are now in development and which are based on this advanced new platform may be introduced to the market. For information that may affect the forward-looking statements made in this paragraph about products under development, see Outlook: Issues and Risks New Products, Manufacture of SAGE Oxygen Therapeutic Device.

In 1998, the Company introduced the TOTAL O2® Delivery System, which provides stationary oxygen for patients at home, portable oxygen, including an oxygen conserving device for ambulatory use, and a safe and efficient mechanism for filling portable oxygen cylinders in the home. This provides home care dealers with a means to reduce their monthly cost of servicing patients while at the same time providing a higher quality of service by maximizing ambulatory capability. The Company received clearance in November 1997 from the Food and Drug Administration to sell this product. Initial sales of the TOTAL O2 system were adversely affected by several factors, including the overall home oxygen market climate as well as start-up manufacturing and related supplier quality issues. The Company has taken a number of steps to resolve the manufacturing and supplier issues and now believes the success of this product will be dependent on the healthcare community's acceptance of this technology and willingness to substitute a higher capital acquisition cost for lower operating costs. While the

---

**Table of Contents**

Company will continue its efforts to promote this product, based on sales levels through March of 2003, the Company wrote off the unamortized license fees related to the TOTAL O2 system in March 2003.

During the past three years, the Company has recovered substantial market share in the conserver market and is using that platform to spearhead its growth strategy for the future, which includes the following:

Development of additional oxygen conserver models, such as the LOTUS Electronic Oxygen Conserving introduced in October 2004, that diversify the product line in order to offer customers a range of oxygen conservation choices;

An effort to expand the Company's product lines and improve existing products through the investment in and development of new technologies, such as proprietary sensor technology and control software licensed in January of 2003 and the introduction of the SAGE Oxygen Therapeutic Device in May 2004. These new technologies should provide the Company with an opportunity to expand its oxygen delivery product lines and potentially enter the high-growth sleep disorder market;

A continued promotional and education campaign with respect to the benefits of the TOTAL O2 system, coupled with an ongoing emphasis on improving the performance of component suppliers.

While the turnaround measures of the past three years have had a positive impact and management believes the current growth strategy should continue to enhance the Company's competitive position and future operating performance, no assurances can be given that these objectives will be achieved. Management of the Company will continually monitor the success of these efforts and will attempt to remain flexible in order to adjust to possible future changes in the market for respiratory care devices. For information that may affect the outcome of forward-looking statements in this Overview regarding the Company's business strategy and its introduction of new products, see Outlook: Issues and Risks - New Products, Consolidation of Home Care Industry, Competition, Rapid Technological Change, and Potential Changes in the Administration of Health Care, beginning on page 16 of this Report.

**Results of Operations**

Net sales for the three and nine month periods ended December 31, 2004 increased by \$1,209,000 (23.1%) and \$2,662,000 (16.4%) respectively, as compared to the same periods in the prior year. The primary driver of the Company's increase in sales has been the significant growth in sales of its conservers and therapeutic devices. Management believes that the performance features of its conservers and therapeutic devices have enabled the Company to recapture significant market share. Domestic unit sales of conservers and therapeutic devices for the three and nine month periods ended December 31, 2004, increased 30% and 41%, respectively over the prior year, while the increase in domestic revenues from conserver sales was 6% and 9%, respectively. This resulted from price reductions, the impact of national chain contract pricing (see above), and the generally lower pricing for pneumatic conservers in the marketplace. As noted above, management expects continued downward pressure on its average selling price.

---

**Table of Contents**

Sales of the SAGE Oxygen Therapeutic Device are increasing. A customer that placed a large order for SAGE devices earlier in the year is taking delivery of the devices at a slower rate than was originally planned. The Company is working with the customer on a revised delivery schedule that will likely stretch into fiscal 2006. In addition, during the three month period ended December 31, 2004, the Company experienced a decline in sales of the OXYMATIC 400 series as a result of reduced orders from a large customer. The Company is pursuing efforts to reverse the decline in orders from this customer. However, at this time it is not clear if the Company's efforts will be successful or if it will experience a continued decline in sales of the OXYMATIC 400 device to this customer. Future operating results may be increasingly dependent upon purchase decisions of a limited number of large customers.

The Company saw significant growth in sales of its TotalO2 Delivery System during the quarter ended December 31, 2004. Upcoming changes in Medicare reimbursement have increased interest in the TotalO2 System as a cost effective way to fulfill home care provider and patient needs. Revenues from TotalO2 sales increased 281% and 97%, respectively, for the three and nine month periods ended December 31, 2004, as compared to the prior year's periods.

Sales to foreign distributors represented 5.2% and 5.0% of total sales for the three month periods ended December 31, 2004 and 2003, respectively, and 5.9% and 4.6% for the nine month periods ended December 31, 2004 and 2003, respectively. Management expects an increase in sales to foreign distributors during the upcoming twelve months; however, quarter-to-quarter sales may fluctuate depending on the timing of shipments. All foreign sales, with the exception of Canada, are denominated in US dollars. Sales in Canada represent less than 2% of total sales.

Cost of sales as a percent of net sales increased from 57.6% to 58.0% for the three month period ended December 31, 2004 and decreased from 59.4% to 59.0% for the nine month period ended December 31, 2004, as compared to the same periods in the prior year. The increase in cost of sales as a percentage of sales for the three month period ended December 31, 2004 as compared to the same period in the prior year is due to a shift in product mix in the third quarter, while the decrease for the nine month period was a result of overhead efficiencies achieved due to production increases related to the increase in sales.

Selling, general and administrative expenditures increased from 27.7% to 28.8% and decreased from 29.5% to 28.2% of net sales for the three and nine month periods ended December 31, 2004, respectively, as compared to the same periods in the prior year. The Company's cost reduction efforts over the past two years have helped align staffing and operating expenses more closely with current sales expectations, but were offset to some extent by commissions paid to the Company's field sales force of manufacturer's representatives. Research and development expenses increased by \$36,000 for the three month period ended December 31, 2004 and \$196,000 for the nine month period ended December 31, 2004, as compared to the same periods in the prior year. Currently, management expects research and development expenditures to total approximately \$1,570,000 in the fiscal year ending March 31, 2005, on projects to enhance and expand the Company's product line. During fiscal year 2004, the Company spent \$1,292,000 on research and development.

---

**Table of Contents**

On July 31, 2002, a national chain accounting for less than 10% of sales in fiscal 2003 filed a Plan of Reorganization under Chapter 11 of the United States Bankruptcy Code (the Plan). The Plan provided for full repayment to the Company, and the Bankruptcy Court approved the Plan. Payments to the unsecured creditors commenced on July 1, 2003. As of December 31, 2004, this debt to the Company had been reduced to approximately \$48,000, and in January 2005 the Company received payment of \$43,000 against the remaining balance.

At December 31, 2004, the Company's net deferred tax assets are partially offset by a valuation allowance. The Company will continue to assess the valuation allowance and to the extent it is determined that such allowance is no longer required, the tax benefit of the remaining net deferred tax assets will be recognized in the future. The Company has California net operating loss carryforwards of \$1,535,000, against which a partial valuation allowance has been recorded. California has suspended the utilization of net operating loss carryforwards during tax years starting in 2002 and 2003. As a result, the company has been unable to use its California net operating loss carryforwards until the tax year which began April 1, 2004. The California net operating losses expire in 2006.

**Financial Condition**

At December 31, 2004, the Company had cash totaling \$2,021,000 or 12.7% of total assets, as compared to \$2,708,000 (20.8% of total assets) at March 31, 2004. Net working capital increased from \$9,175,000 at March 31, 2004 to \$10,499,000 at December 31, 2004. Net accounts receivable increased \$717,000 during the nine months ended December 31, 2004, due to the increase in sales. Future increases or decreases in accounts receivable will generally coincide with sales volume fluctuations and the timing of shipments to foreign customers. During the same period, inventories increased \$2,368,000, in significant part as a result of the Company's efforts to fill a large purchase order for SAGE devices. Delivery of units pursuant to that purchase order have been stretched out beyond the originally contemplated timetable. The Company attempts to maintain sufficient inventories to meet its customer needs as orders are received. Thus, future inventory and related accounts payable levels will be impacted by the ability of the Company plan for anticipated orders and to maintain its safety stock levels. If safety stock levels drop below target amounts, then inventories in subsequent periods will increase more rapidly as inventory balances are replenished. Currently, inventory balances are generally near safety stock levels.

The Company depends upon its cash flow from operations to meet its capital requirements. Management believes cash balances and funds derived from operations should be adequate to meet the Company's near and long term cash requirements given the Company's recent operating performance. Cash derived from operations will depend on the ability of the Company to maintain profitable operations and the timing of increases in receivables and inventories. If profitable operations do not continue, the Company may need to seek other sources of working capital. Historically, the Company has financed its inventory requirements out of cash flow and it has not sought to finance its accounts receivable. It is possible the Company might seek financing arrangements for working capital in the future. The Company has no established lines of credit or other arrangements in place to obtain working capital and no assurance can be given that if and when needed other sources of working capital would be available. The Company expects capital expenditures during the next twelve months to be approximately \$1,250,000.

---

**Table of Contents**

The following table aggregates all of the Company's material contractual obligations as of December 31, 2004:

| Contractual<br>Cash Obligations | Payments Due by Period |                     |                |              |                     |
|---------------------------------|------------------------|---------------------|----------------|--------------|---------------------|
|                                 | Total                  | Less than 1<br>Year | 1 - 3<br>Years | 3-5<br>Years | After<br>5<br>Years |
| Operating lease obligations     | \$ 1,412,000           | \$ 418,000          | \$ 994,000     |              |                     |

Operating lease commitments consist primarily of a real property lease for the Company's corporate office, as well as minor equipment leases. Payments for these lease commitments are provided for by cash flows generated from operations. Please see Note 8 to the financial statements in the 2004 Annual Report.

The Company does not have any debt and is not subject to any covenants or contractual restrictions limiting its operations. The Company has not adopted any programs that provide for post employment retirement benefits, however, it has on occasion provided such benefits to individual employees. The Company does not have any off balance sheet arrangements with any special purpose entities or any other parties, does not enter into any transactions in derivatives and has no material transactions with any related parties.

**Critical Accounting Policies**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates under different assumptions and conditions. Management believes that the following discussion addresses the accounting policies and estimates that are most important in the portrayal of the Company's financial condition and results.

**Allowance for doubtful accounts** – the Company provides a reserve against receivables for estimated losses that may result from our customers' inability to pay. The amount of the reserve is based on an analysis of known uncollectible accounts, aged receivables, historical losses, and credit-worthiness. Amounts later determined and specifically identified to be uncollectible are charged or written off against this reserve. The likelihood of material losses is dependent on general economic conditions and numerous factors that affect individual accounts.

**Inventories** – the Company provides a reserve against inventories for excess and slow moving items. The amount of the reserve is based on an analysis of the inventory turnover for individual items in inventory. The likelihood of material write-downs is dependent on customer demand and competitor product offerings.

**Intangible and long-lived assets** – The Company assesses whether or not there has been an impairment of intangible and long-lived assets in evaluating the carrying value of these assets. Assets are considered impaired if the carrying value is not recoverable over

**Table of Contents**

the useful life of the asset. If an asset is considered impaired, the amount by which the carrying value exceeds the fair value of the asset is written off. The likelihood of a material change in the Company's reported results is dependent on each asset's ability to continue to generate income, loss of legal ownership or title to an asset and the impact of significant negative industry or economic trends.

Deferred income taxes – the Company provides a valuation allowance to reduce deferred tax assets to the amount expected to be realized. The likelihood of a material change in the expected realization of these assets depends on the Company's ability to generate future taxable income.

**Outlook: Issues & Risks**

The report contains forward-looking statements, which reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are subject to certain risks and uncertainties, which may cause actual operating results to differ materially from currently anticipated results. Among the factors that could cause actual results to differ materially are the following:

**Dependence Upon a Single Product Line**

Although the Company currently markets a number of products, these products comprise a single product line for patients requiring supplementary oxygen. The Company's future performance is thus dependent upon developments affecting this segment of the health care market and the Company's ability to remain competitive within this market sector.

**New Products**

The Company's future growth in the near term will depend in significant part upon its ability to successfully introduce new products. In recent years, the Company has introduced the OXYMATIC 400 series, the SEQUOIA, CYPRESS OXYPneumatic, and LOTUS conservers, and the TOTAL O2 Delivery System and in May 2004 introduced the SAGE Oxygen Therapeutic Device; the Company is currently developing additional new products. The success of the Company's products will depend upon the health care community's perception of such products' capabilities, clinical efficacy and benefit to patients as well as obtaining timely regulatory approval for new products. In addition, prospective sales will be impacted by the degree of acceptance achieved among home oxygen dealers and patients requiring supplementary oxygen. As with any product, the Company's ability to successfully promote new products cannot be determined at this time.

**Manufacture of SAGE Oxygen Therapeutic Device**

In May 2004, CHAD received clearance for the FDA to market the SAGE Oxygen Therapeutic Device. Customer response to this new product has been positive, and the Company has received purchase orders that will consume its SAGE product capability through January 2005. As the Company ramps its production capabilities to meet demand for the SAGE device, it may encounter difficulties in securing components, scaling production facilities or other aspects of managing growth in manufacturing operations. Unexpected problems or costs could adversely affect the Company's gross profit margins or its ability to meet customer demand on a timely basis. Failure to meet customer demand on a timely basis could result in lost orders or could harm the Company's reputation.

**Table of Contents**

**Consolidation of Home Care Industry**

The home health care industry is undergoing significant consolidation. As a result, the market for the Company's products is increasingly influenced by major national chains. Four major national chains accounted for 54% of the Company's net sales during the year ended March 31, 2004 and for 49% of net sales for the nine months ended December 31, 2004. Future sales may be increasingly dependent upon a limited number of customers, which may reduce our average selling price due to quantity pricing and which may result in greater volatility and less predictability of the Company's operating results. Moreover, the loss of a major customer or a significant decline in orders from a major customer could have a material adverse effect upon the Company's revenues and profitability..

**Competition**

The Company's success in the early 1990's has drawn competition to vie for a share of the home oxygen market. These new competitors include both small and very large companies. While the Company believes the quality of its products and its established reputation will continue to be a competitive advantage, some competitors have successfully introduced lower priced products that do not provide oxygen conserving capabilities comparable to the Company's products. Most of these competitors have greater capital resources than the Company. No assurance can be given that increased competition in the home oxygen market will not have an adverse affect on the Company's operations.

**Rapid Technological Change**

The health care industry is characterized by rapid technological change. The Company's products may become obsolete as a result of new developments. The Company's ability to remain competitive will depend to a large extent upon its ability to anticipate and stay abreast of new technological developments related to oxygen therapy. The Company has limited internal research and development capabilities. Historically, the Company has contracted with outside parties to develop new products. Some of the Company's competitors have substantially greater funds and facilities to pursue research and development of new products and technologies for oxygen therapy.

**Potential Changes in Administration of Health Care**

A number of proposals to regulate, control or alter the method of financing health care costs have been discussed and certain such bills have been introduced in Congress, and various state legislatures. Because of the uncertain state and widely varying terms of health care proposals, it is not meaningful at this time to predict the effect on the Company if any of these proposals is enacted.

Approximately 80% of home oxygen patients are covered by Medicare and other government programs. Federal law has altered the payment rates available to providers of Medicare services in various ways during the last several years. In November of 2003, Congress enacted the Medicare Improvement and Modernization Act, which will cause changes and reductions in home oxygen reimbursement over the next several years. These changes in reimbursement will cause increased downward pressure on the average selling price of the Company's products.

---

**Table of Contents**

**Protection of Intellectual Property Rights**

The Company pursues a policy of protecting its intellectual property rights through a combination of patents, trademarks, trade secret laws and confidentiality agreements. The Company considers the protection of its proprietary rights and the patentability of its products to be significant to the success of the Company. To the extent that the products to be marketed by the Company do not receive patent protection, competitors may be able to manufacture and market substantially similar products. Such competition or claims that the Company's products infringe the patent or trademark rights of others could have an adverse impact upon the Company's business.

**Product Liability**

The nature of the Company's business subjects it to potential legal actions asserting that the Company is liable for damages for product liability claims. Although the Company maintains product liability insurance in an amount which it believes to be customary in the industry, there is no assurance that this insurance will be sufficient to cover the cost of defense or judgments which might be entered against the Company. The type and frequency of these claims could have an adverse impact on the Company's results of operations and financial position.

**Availability and Reliability of Third Party Component Products**

The Company tests and packages its products in its own facility. Some of its other manufacturing processes are conducted by other firms; the Company expects to continue using outside firms for certain manufacturing processes for the foreseeable future and is thus dependent on the reliability and quality of parts supplied by these firms. From time to time, the Company has experienced problems with the reliability of components produced by third party suppliers. The Company's agreements with its suppliers are terminable at will or by notice. The Company believes that other suppliers would be available in the event of termination of these arrangements. No assurance can be given, however, that the company will not suffer a material disruption in the supply of parts required for its products.

**Accounting Standards**

Accounting standards promulgated by the Financial Accounting Standards Board change periodically. Changes in such standards may have an impact on the Company's future financial position.

In November 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No 151 (Inventory Costs), an amendment of ARB No. 43, Chapter 4. The statement clarifies accounting for abnormal amounts of idle facility expense, freight, handling costs and spoilage and requires those items to be expensed when incurred. SFAS 151 is applicable to inventory costs incurred during fiscal years beginning after June 15, 2005. The Company has not yet determined if the adoption of this standard will have a significant impact on its financial statements.

In December 2004, the Financial Accounting Standards Board issued Statement of Financial Accounting Standard (SFAS) No. 123R (Share-Based Payment). SFAS 123R requires the Company to recognize compensation expense based on the fair value of equity instruments awarded to employees. We will adopt SFAS 123R on July 1, 2005, and the Company does not anticipate a significant impact to its financial statements.

---

**Table of Contents**

**Additional Risk Factors**

Additional factors, which might affect the Company's performance, may be listed from time to time in the reports filed by the Company with the Securities and Exchange Commission.

**Item 3. Quantitative and Qualitative Disclosures about Market Risks**

The Company has no significant exposure to market risk sensitive instruments or contracts .

**Item 4. Controls and Procedures**

The Company has evaluated the effectiveness of the design and operation of its disclosure controls and procedures as of December 31, 2004 (the Evaluation Date ). Such evaluation was conducted under the supervision and with the participation of the Company's Chief Executive Officer ( CEO ) and its Chief Financial Officer ( CFO ). Based upon such evaluation, the Company's CEO and CFO have concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective to ensure that we record, process, summarize, and report information required to be disclosed by us in our quarterly reports filed under Securities Exchange Act within the time periods specified by the Securities and Exchange Commission's rules and forms. There have been no significant changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Part II**

**Other Information**

**Item 1. Legal Proceedings**

None.

**Item 2. Changes in Securities, Use of Proceeds and Issuer Purchase of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities**

Not applicable.

**Item 4. Submission of Matters to a Vote of Security Holders**

None

Item 5. Other Information

None.

---

**Table of Contents**

Item 6. Exhibits

(a) 31.1 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CEO

(b) 31.2 Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CFO

(c) 32\* Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002

The information in Exhibit 32 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this quarterly report), unless CHAD Therapeutics specifically incorporates the foregoing information into those documents by reference.

---

**Table of Contents**

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHAD THERAPEUTICS, Inc.

\_\_\_\_\_  
(Registrant)

Date 02/10/2005

/s/ Earl L. Yager  
\_\_\_\_\_

Earl L. Yager  
President and Chief Executive Officer

Date 02/10/2005

/s/ Tracy A. Kern  
\_\_\_\_\_

Tracy A. Kern  
Chief Financial Officer

\_\_\_\_\_

**Table of Contents**

INDEX TO EXHIBITS

| Exhibit No. | Description of Exhibits   |
|-------------|---|
| 31.1        | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CEO                                       |
| 31.2        | Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002 for CFO                                       |
| 32*         | Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 |

\*The information in Exhibit 32 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act (including this quarterly report), unless CHAD Therapeutics specifically incorporates the foregoing information into those documents by reference.

Certification pursuant to 18 U.S.C Section 1350